AMRA Medical and Fulcrum Therapeutics have partnered to create an MRI tool that evaluates skeletal muscle composition in patients with a form of slowly progressing muscular dystrophy.
In a clinical study, the two companies created and tested a detailed whole-body MRI protocol to evaluate the muscles of patients with facioscapulohumeral dystrophy. The protocol can quantify muscle fat fraction, lean muscle volume, and muscle fat infiltration.
The new protocol can improve upon the limitations of functional walk tests and single-slice MRI, according to Fulcrum leadership. In addition, MRI may be able to detect fat and muscle changes earlier and more accurately than other tests.